12/5
03:31 pm
nxl
Nexalin Technology, Inc. (NASDAQ: NXL) had its "hold" rating re-affirmed by analysts at Maxim Group.
Low
Report
Nexalin Technology, Inc. (NASDAQ: NXL) had its "hold" rating re-affirmed by analysts at Maxim Group.
11/26
10:15 am
nxl
New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market [Yahoo! Finance]
Low
Report
New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market [Yahoo! Finance]
11/26
10:00 am
nxl
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Low
Report
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
11/11
08:00 am
nxl
Nexalin Technology CEO Provides Letter to Shareholders
High
Report
Nexalin Technology CEO Provides Letter to Shareholders
11/10
08:50 am
nxl
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth? [Yahoo! Finance]
High
Report
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth? [Yahoo! Finance]
11/1
02:00 pm
nxl
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
Medium
Report
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
11/1
10:34 am
nxl
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
High
Report
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
10/28
08:30 am
nxl
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
Low
Report
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
10/28
08:09 am
nxl
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients [Yahoo! Finance]
Low
Report
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients [Yahoo! Finance]
10/25
09:00 am
nxl
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Medium
Report
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10/22
02:20 pm
nxl
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA [Yahoo! Finance]
Medium
Report
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA [Yahoo! Finance]
10/22
02:15 pm
nxl
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
Medium
Report
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
10/17
08:30 am
nxl
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
High
Report
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
10/17
08:12 am
nxl
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study [Yahoo! Finance]
High
Report
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study [Yahoo! Finance]
10/14
08:30 am
nxl
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
High
Report
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
10/9
08:33 am
nxl
Nexalin Technology, Inc. (NASDAQ: NXL) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Nexalin Technology, Inc. (NASDAQ: NXL) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock.